Outlining the big questions and considerations for pharma companies in determining their readiness for this transformation—and achieving true “AI Advanced” status.
Shravan Kotakonda
Advertisement
VP, Strategic Operations, Commercial Solutions, IQVIA
Articles by Shravan Kotakonda
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
2
Augmentin XR Becomes First Approval Under Commissioner’s National Priority Voucher Pilot Program
3
Pfizer Enters Exclusive Collaboration and License Agreement with Yao Pharma for Oral Small-Molecule GLP-1 Agonists
4
Actionable Insights at the Point of Care: A New Era in Provider Engagement
5
